Introduction and hypothesis Many adult women have resident urinary bacteria (urinary microbiome/microbiota). In adult women affected by urinary urgency incontinence (UUI), the etiologic and/or therapeutic role of the urinary microbiome/microbiota remains unknown. We hypothesized that microbiome/microbiota characteristics would relate to clinically relevant treatment response to UUI medication per os. Methods Adult women initiating medication treatment orally for UUI and a comparator group of unaffected women were recruited in a tertiary care health-care system. All participants provided baseline clinical data and urine samples. Women with UUI were given 5 mg solifenacin, with potential dose escalation to 10 mg for inadequate UUI symptom control at 4 weeks. Additional data and urine samples were collected from women with UUI at 4 and 12 weeks. The samples were assessed using 16S ribosomal RNA (rRNA) gene sequencing and enhanced quantitative urine culturing. The primary outcome was treatment response as measured by the validated Patient Global Symptom Control (PGSC) questionnaire. Clinically relevant UUI symptom control was defined as a 4 or 5 score on the PGSC. Results Diversity and composition of the urinary microbiome/ microbiota of women with and without UUI differed at baseline. Women with UUI had more bacteria and a more diverse Krystal J. Thomas-White and Evann E. Hilt contributed equally to this work.
Introduction
Many adult women undergo treatment for urinary urgency incontinence (UUI), often with orally administered anticholinergic medication such as solifenacin [1] . This medication class targets M3 muscarinic receptors to decrease smooth muscle contraction, relieving UUI symptoms of urgency, frequency, and urgency incontinence [1] . Although solifenacin decreases urgency episodes in approximately 60 % of treated patients, symptoms may persist [2] [3] [4] , with approximately 40 % of treated patients reporting bothersome symptoms [5] . Clinicians recognize this lack of response, although the cause remains unclear, and studies into the biologic basis for persistent symptoms are lacking. Many UUI-affected patients are considered to have idiopathic etiology; however, this view predates emerging evidence of resident urinary bacterial communities (urinary microbiota) [6] [7] [8] . DNA sequencing and expanded urine culture techniques have demonstrated that adult urine is not sterile [6, [9] [10] [11] [12] [13] [14] [15] [16] and that UUI-affected women have different resident bacterial compositions than do nonUUI control populations [11] .
In this prospective cohort of adult women with UUI, we compared baseline urinary microbiota of women with UUI to those of unaffected controls. For UUI-affected women subsequently undergoing clinically indicated UUI treatment with solifenacin, we also determined urinary microbiota profiles throughout 12 weeks of treatment using additional longitudinal samples collected at 4 and 12 weeks. We hypothesized that the microbiome/microbiota (e.g., diversity, overall community structure, and/or specific organisms) would differ between women with and without UUI and between those who responded to solifenacin and those who did not. Two complementary bacterial assessments, sequencing and expanded quantitative urine cultures (EQUC) [10] , were used to overcome the insensitivity of standard urine cultures. EQUC was not initially available; however, once this technique was available, it was applied to all remaining samples.
Methods

Study design and population
This 12-week open-label study began following Institutional Review Board approval. Participants gave verbal and written research consent for chart abstraction and urine collection with analysis for research purposes. Between August 2012 and July 2014, two cohorts of adult women were recruited at a tertiary health-care setting (Loyola University Medical Center). Potential participants were screened for eligibility using the long version of the validated Pelvic Floor Distress Inventory (PFDI) [17, 18] . Women seeking UUI treatment were recruited from a specialty Female Pelvic Medicine and Reconstructive Surgery center. Comparison controls screened negative for UUI using the PFDI and were recruited from women's health practices within Loyola's system. These controls were derived from a population of gynecologic patients; those who underwent surgical procedures had a variety of benign gynecologic conditions, most commonly abnormal uterine bleeding confirmed to be of a benign nature. Enrolled participants also completed the Overactive Bladder Questionnaire (OAB-Q) [19] . Exclusion criteria for both cohorts were current urinary tract infection (UTI) (based on urine dipstick), history of recurrent UTI, antibiotic exposure in the past 4 weeks for any reason, immunologic deficiency, neurological disease known to affect the lower urinary tract, pelvic malignancy or radiation, untreated symptomatic pelvic organ prolapse (POP) greater than POP Quantification system (POP-Q) stage II (vaginal protrusion >1 cm outside of the vaginal hymen) or pregnancy.
Control participants, without overactive bladder symptoms, provided a single catheterized urine sample for research purposes and clinical and questionnaire data. As part of normal clinical care, UUI-affected participants provided a catheterized urine sample prior to UUI treatment with solifenacin, which was provided at no cost for 12 weeks. Participants with UUI also agreed to provide two additional catheterized urine samples at 4 and 12 weeks during UUI treatment for longitudinal analysis. The primary outcome was treatment response at 12 weeks assessed (at 4 and 12 weeks) using the validated Patient Global Symptom Control (PGSC) questionnaire [20] , which consists of a single question that addresses improvement following treatment. Scores of 4 or 5 were defined as Bresponse,^and scores ≤3 were considered Bnonresponse;t hese participants were offered a dosage increase to 10 mg at 4 weeks. Women with a PGSC score ≥4 continued solifenacin 5 mg dose for 8 more weeks until primary outcome assessment at 12 weeks. Thus, definitions for three response groups were determined a priori: nonresponders, 5-mg responders, and 10-mg responders. Participants who were intolerant of the medication could withdraw at any point during the study. The research team assessed adverse events at normally scheduled visits and at other intervals during participant-initiated contact. Figure 1 shows the flow of UUI-affected study participants. The primary outcome was symptomatic response based on PGSC score at 12 weeks.
Sample collection and analysis
Urine was collected aseptically via transurethral catheter and a portion placed in a BD Vacutainer Plus C&S preservative tube for culture. Urine culture was performed as described [10] (EMethods 1). A separate aliquot for sequencing was placed at 4°C for ≤4 h following collection; 10 % AssayAssure (Sierra Molecular; Incline Village, NV, USA) was added before storage at −80°C. Our protocols for DNA extraction, library construction, 16S ribosomal RNA (rRNA) sequencing, and bioinformatics analysis were as described [11] . All genomic samples were processed in duplicate, and analysis was performed using mothur software [21] . Relative abundance was calculated by generating the percent of total classified reads for each individual. All samples were processed in duplicate, and the percent reads of replicates were averaged for downstream analysis, which included urotype identification and statistical analysis. Urotypes were determined as described [11] . Briefly, a culture urotype is determined by the dominant (>50 %) identified organisms within a given sample. A sequencing urotype is determined by first clustering sequences using a dendrogram and grouping based on similarity; this usually correlates with dominance (>50 %) of one organism.
Those communities without a dominant organism were classified as Bdiverse^urotype. Dendrograms were calculated using Bray Curtis dissimilarity between samples, and the complete method was used for hierarchical clustering via R software, version 2.15.1 [22] . To measure the diversity (richness and evenness of species within a sample), the alpha diversity (inverse Simpson's index) was calculated using mothur software [21] .
Protocol for expanded quantitative urine culture (EQUC)
For standard urine culture, 0.001 ml of urine was spread quantitatively onto 5 % sheep blood [blood agar plate (BAP)] and MacConkey agars (BD BBL™ Prepared Plated Media) then incubated aerobically (35°C for 24 h). Any amount of each separate morphologic colony type was identified and counted using a detection level of 1,000 colony forming units (CFU)/ ml (represented by 1 colony of growth on either plate). BNo growth^was reported when no growth was observed, indicating no growth of bacteria at lowest dilution, i.e., 1:1000.
The EQUC technique uses 0.1 ml of urine spread quantitatively onto BAP, chocolate, and colistin-nalidixic acid (CNA) agars (BD BBL™ Prepared Plated Media), then incubated in 5 % CO 2 (35°C for 48 h). A second set of BAPs was inoculated with 0.1 ml of urine and incubated in room atmosphere at 30°C for 48 h. In addition, 0.1 ml of urine was inoculated onto each of two CDC Anaerobe 5 % sheep blood agar (ABAP) plates (BD BBL™ Prepared Plated Media) and incubated in either a Campy gas mixture (5 % O 2 , 10 % CO 2 , 85 % N) or in anaerobic conditions at 35°C for 48 h. The detection level was 10 CFU/ml, represented by one colony of growth on any of the plates. Finally, to detect any bacterial species that may be present at quantities <10 CFU/ml, 1.0 ml of urine was placed in thioglycollate medium (BD BBL™ Prepared Tubed Media) and incubated aerobically at 35°C for 5 days. If growth was detected visually, the thioglycollate medium was mixed, a few drops plated on BAP and ABAP agars for isolation, and plates incubated aerobically and anaerobically (35°C for 48 h). Each morphologically distinct colony type was isolated on a different plate of the same medium to prepare a pure culture for organism identification. Matrixassisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) with the MALDI Biotyper 3.0 software (Bruker Daltonics, Billerica, MA, USA) was used to identify bacterial isolates [10] . To determine the false-negative rate, the following equation was used: number of EQUC-positive but standard negative samples divided by the total number of EQUC-positive samples. To determine culture diversity within a population, a species accumulation curve was generated, which illustrated the number of unique species cultured and identified (using EQUC) with each new patient sampled. When the curve plateaus, it indicates that the community is fully sampled, and few, if any, new species will be identified. Therefore, it also measures the overall diversity of the population by total number of unique species isolated.
Statistical analyses
Standard statistical methods were used to compare participant demographics and symptom data between UUI patients and controls. Continuous variables are reported as means and standard deviations (SD) or medians and interquartile ranges (IQR); categorical variables are reported as frequencies and percentages. Collection of primary outcomes at 12 weeks was necessary for assignment to UUI-response groups; therefore, participants who did not provide data through 12 weeks were not included in analyses involving response to solifenacin. Fisher's exact and Kruskal-Wallis tests were used to compare demographic and culture (e.g., abundance and diversity) information among UUI response groups. For cultured organisms, abundance was measured using total CFU/ ml; for sequencing, abundance was measured using percent classified reads or classified organisms. Post hoc pairwise comparisons were made using Wilcoxon rank sum tests for continuous variables with significant overall p values. A kappa statistic was estimated to determine agreement between urotype classification from samples with both EQUC and sequencing. All statistical analyses were conducted using SPSS software version 19 or SAS software v9.4 (SAS Institute, Cary, NC, USA). Significance was assessed at an alpha level of 0.05. Results were not adjusted for multiple comparisons, since analyses are considered descriptive.
Results
Population description over the course of the study Figure 1 displays the flow of UUI study participants through the 12-week follow-up period. Study investigators withdrew participants who had received antibiotics for unrelated clinical indications (2) and those who underwent a cystoscopy for clinical indications (2) . An additional 17 participants withdrew by the 4-week visit: seven due to side effects and six lost to follow-up. Of participants who provided UUI symptom-response data at 4 weeks, 56 % (32/57) reported adequate symptom control; the remaining 25 accepted dose escalation (to 10 mg daily).
Comparison of baseline UUI to controls
At baseline, participants included 74 UUI-affected women and 60 controls. The cohorts were similar with respect to race/ethnicity, diabetes, and smoking (Table 1) . Participants with UUI were more likely to have hypertension (35 % versus 18 %, p=0.02) and coronary artery disease (12 % versus 2 %, p=0.02). The UUI population also was older (61.5 years [SD 11.5] versus 49 [SD 14.7] , p<0.001), heavier: body mass index (BMI) 32.7 (SD 8.4) versus 28 (SD 5.5) (p<0.001) and were more likely to be estrogen-negative (postmenopausal and not on hormone replacement therapy) (88 % versus 43 %, p <0.001). As expected, UUI symptoms were significantly worse in UUI than non-UUI participants.
We detected the presence of bacterial DNA in a similar proportion of urine samples for each cohort (controls 43 %, N = 26/60, UUI 50 %, N = 37/74; p = 0.44) (Table 2A) . Table 2A and E display the assigned sequence urotypes. In both groups, the majority of samples were dominated by Lactobacillus [controls 61.5 %, N=16/26, UUI 40.5 %, N= 15/37; p=0.13]. Alpha diversity (measured by the inverse Simpson index) of classified sequences between UUI and controls was similar (p=0.76).
A large subset of baseline samples was processed by EQUC (UUI, N=59/74, control, N=52/60). A greater proportion of UUI-affected women had cultivatable bacteria in their urine compared with control women (84.7 % versus 63.5 %, p=0.01). The groups differed in proportion of cultured samples characterized by dominant organisms (culture urotypes) (Table 2A) : Lactobacillus (controls 45.5 %, N=15/33 versus UUI 22 %, N=11/50; p=0.03), and diverse (controls 6 %, N= 2/33)versus UUI 32 %, 16/50; p=0.006) (Table 2A) . Relative to controls, UUI-affected women had significantly more diversity in unique cultivatable organisms as assessed by the number of unique cultivatable organisms per cohort (UUI, N =80, controls, N=36, Fig. 2 ), significantly more cultured bacterial isolates per participant as measured by the median [UUI (3; IQR 1-7) versus controls (1; IQR 1-2), p<0.001, Fig. 2 Table 1 ). We did not detect other significant group differences in baseline variables for participants who competed the study (E- Table 1 ). At baseline, the three response groups had similar demographics and symptom severity (Table 1) . At 12 weeks, HRQL scores differed among all response groups (p=0.008). The median score for nonresponders (70, IQR 61-86) differed significantly from both responder groups: 5-mg group (93, IQR 86-99) and 10-mg group (94, IQR 88-99) (p=0.004 and p=0.008, respectively) ( Table 1) . Urine samples from all 50 participants with primary outcome data were tested for detectable bacteria. At baseline, a similar proportion of each response group had detectable bacterial DNA (5 mg 56 %, N=14/25, 10 mg 46.7 %, N=7/15, nonresponders 40 %, N=4/10; p=0.66) (Table 2B ), suggesting that there is no difference in the frequency of samples with detectable bacteria present in each response group. In contrast, when we compared bacterial community composition by distribution of urotypes (i.e., number of individuals with microbiomes dominated by one organism), baseline samples from each response group tended to be different; however, no statistical testing was conducted due to limited sample sizes. Compared with 10-mg responders (12.5 %, N=1/8), 5-mg responders had a larger proportion of individuals with Lactobacillus-dominant urine (50 %, N=7/14) ( Table 2B ). The response groups had similar alpha diversities: 5 mg 1.6 (IQR 1.2-3.7), 10 mg 1.9 (IQR 1.1-6.3), nonresponders 2.8 (IQR 1.7-4.1) (p=0.55).
The subset of baseline urine samples from participants with primary outcome data cultured with EQUC (N=39/50) included 19 responders at 5 mg, 13 at 10 mg, and seven nonresponders. Cultivatable organisms (EQUC) were detected in most participants: 5-mg responders 73.7 % (N=14/19), 10-mg responders 100 % (N=13/13), and nonresponders 85.7 % (N= 6/7) (p=0.13, Table 2B ). The dominant urotype by response group was: 5-mg response Lactobacillus-dominant urotype 35.7 % (N=5/14); 10-mg diverse urotype 38.5 % (N=5/13), and 30.8 % (N=4/13) Streptococcus-dominant urotype; nonresponders showed diverse urotype 50 % (N=3/6). Each response group had a distinct species accumulation curve, with different total number of unique cultured bacterial isolates: 5 mg (32), 10 mg (54), and nonresponders (42) (Fig. 2) . Overall, there was a difference in the number of unique species isolated by response group (p=0.02). The median number of unique species isolated from each individual within each cohort was similar in the 10-mg-responder and nonresponder groups (5 versus 8, p=0.25 Fig. 2 inset) . However, there was a statistically significant difference between the 5-mg and other responder groups: 5-mg responders one versus 10-mg responders five (p=0.03) or nonresponders eight (p=0.02) (Fig. 2 inset) .
Each response group contained several genera that differed from other response groups (Fig. 3a) , with Actinomyces cultivated more commonly from 10-mg responders and nonresponders than from 5-mg responders (p=0.01 and 0.04, respectively). Streptococcus was cultivated more frequently f r o m t h e 1 0 -m g r e s p o n d e r s ( p < 0 . 0 0 1 ) , w h i l e Corynebacterium was cultivated more commonly from nonresponders (p=0.002). In addition, several bacterial species differed between response groups (Fig. 3b) .
Primary outcome comparison: 12 weeks
At 12 weeks, 48 of the 50 participants with primary outcome data were sequenced. Two samples were not sequenced due to inconclusive labeling. Of the remaining 48, 23 samples were positive for bacterial DNA (Table 2B) . Similar to baseline, response groups had similar proportions of 12-week samples with detectable bacterial DNA (5 mg 43.5 %, N=10/23; 10 mg 46.7 %, N=7/15; nonresponders 60 %, N=6/10; p= 0.70). Statistical testing was not performed because of limited sample size; however, the three response groups trended toward different sequence urotype distributions, with larger proportions of Lactobacillus urotypes in 5-mg responders (70 %, Of the samples collected, 7 were cultured with EQUC *Undetermined urotype means the bacterial load in the sample was below the detectable threshold by either sampling method **50 patients returned for the 12-week visit, however, only 48 were sequenced due to unclear specimen labeling. These two samples were processed by EQUC N=7/10) compared with 10-mg responders (28.6 %, N=2/7) and nonresponders (33.3 %, N=2/6) ( Table 2B) . Response groups had similar alpha diversity (p=0.18).
At 12 weeks, most (86 %, N=38/44) EQUC-characterized urine samples demonstrated cultivatable organisms (Table 2B) , and each response group tended toward different culture urotype distributions: 5-mg response -Lactobacillusdominant urotype 38.9 %, N=7/18; 10-mg -diverse urotype 23.1 %, N=3/13, and 23.1 %, N=3/13 Streptococcus-dominant urotype; nonresponders -Lactobacillus 42.8 %, N=3/7 (Table 2B ). Species accumulation analysis of baseline and 12-week samples show that the 10-mg and nonresponder groups had a decrease in species diversity by 12 weeks-from 55 unique isolates to 23 for the 10-mg group and from 40 to 29 for the nonresponders. In contrast, the 5-mg group increased in species diversity-from 32 unique isolates to 41 (E- Fig. 1) . No specific single genus significantly declined in either of the responding groups (5 mg or 10 mg) (E- Fig. 2 ). At the conclusion of specimen collection, we compared the two methods of bacterial assessment. Approximately half (49.8 %, N=119/ 239) of all urine specimens sequenced had detectable bacterial DNA, whereas most specimens (80 %, N=140/177) cultured with EQUC grew organisms. Among sequence-positive, culture-positive individuals, urotype classifications were moderately comparable (Kappa=0.45) [23] .
When comparing EQUC to standard culture, we found EQUC detected more organisms overall. Of all urine samples in the study, 81.3 % (N=165/203) grew bacteria by EQUC. Of those, 149 had been deemed culture negative (no growth) by the standard culture, resulting in 90.3 % false-negative rate for standard culture.
Discussion
The female urinary microbiota in women affected by UUI appears to differ from a comparison group of unaffected women. Using two complementary techniques, we assessed differences in composition (urotype), diversity (number of unique bacterial species), and identity of certain bacteria at the genus and species levels. These differences, which were detectable When the curve plateaus, it indicates that the community is fully sampled and few, if any, new species will be identified. Therefore, it also measures the overall diversity of the population by total number of unique species isolated. The urgency urinary incontinence (UUI) curve represents samples at baseline from individuals who may or may not respond. When we divide this curve into each group stratified by response, we see that baseline diversity of each groups is distinct, suggesting that baseline diversity could be predictive of treatment response. The 5-mg responders (grey triangles) had low diversity, with a total of 32 unique species isolated. The 10-mg responders (dark x) had high diversity, with a total of 54 unique isolates. Nonresponders (light x) had high diversity, with a total of 42 unique isolates. The median number of unique species was not significantly different between 10-mg responders and nonresponders: prior to UUI treatment, appear to be related to treatment response. Moreover, following UUI treatment, certain microbiota characteristics appear to be associated with a clinically significant response to treatment. Overall, less diversity appears to be associated with fewer UUI symptoms and with treatment response at 5 mg. We also found that bacterial diversity in women who required a higher dose to achieve adequate symptom control is somewhat similar to the diversity found in nonresponders, indicating that the diversity of cultivatable organisms might be used to predict treatment response.
The mechanistic relationship between bacterial diversity and UUI symptoms is unknown. However, given our findings, important clinical questions regarding UUI etiology or consequences will need careful study. In this research work, we selected two complementary study techniques to assess the bacterial milieu, one of which was developed after we started enrollment. Sequencing, which was available at the onset of our study, provided a broad picture of bladder bacteria, allowing a more complete analysis of bacterial diversity. In addition, sequencing could detect bacteria that even EQUC could not cultivate. However, urine samples contain low biomass relative to other anatomical sites (e.g., gut or vagina). Thus, a proportion of the study population did not contribute sequencing data. This lack of information was often overcome by the use of EQUC. This expanded culture technique for urine became available after our study started. EQUC not only confirms that bladder organisms are alive but allows phenotyping of low-biomass individuals not measurable by sequencing.
The very low CFUs associated with UUI may prompt consideration of a lower CFU cutoff (perhaps >10
2 ) for a standard urine culture. Others have suggested lowering the culture threshold for UTI [15, [24] [25] [26] [27] and even for UUI [28] ; however, these studies focused on growing known uropathogens. Here, we show that the bladder can contain a variety of organisms. Some are likely nonpathogenic normal flora; others might have an impact on UUI and other lower urinary tract symptoms. Some of these might be protective, whereas others may contribute to symptoms. Indeed, we recently reported that detection of urinary microbiota by quantitative Fig. 3 Detection frequency of genera and significant species between response groups: Comparison of frequency of culture-based detection at genus (a) and species (b) levels for baseline urine by response group. Fisher's exact test was used to calculate p values. * p=0.05; ** p=0.00 polymerase chain reaction (PCR) is associated with a reduced risk of postinstrumentation UTI [9] and an association between L. crispatus and the lack of lower urinary tract symptoms [11] . Furthermore, several bacterial species appear to be associated with UUI [11] . Thus, we recommend the use of expanded culture conditions until our understanding of unrecognized uropathogens improves. EQUC is more likely than sequencing to be readily available in the clinical setting and may prove useful for rapid phenotyping of individual patients prior to treatment selection. This is especially important, as no single clinical demographic variable adequately predicted treatment outcome.
We considered the implications of the minority of samples that were Bnegative^for both techniques. We currently consider this group to be Bsub-threshold^rather than Bsterile^and we fully anticipate that very low biomass individuals will be more fully described as technologies evolve.
T h e d o m i n a n c e o f c e r t a i n g e n e r a , s u c h a s Lactobacillus and Gardnerella, may prompt thoughts of vaginal contamination. Our use of aseptically collected specimens via transurethral catheter inserted by experienced individuals, and our prior publications demonstrating the presence of Lactobacillus and Gardnerella in female bladder urine collected through suprapubic aspirates [12] , supports the evidence that both genera are capable of residing in the bladder. The role of these organisms as members of the urinary microbiome and their relationships to vaginal microbiota requires further study. Because the bladder and vagina can contain the same species, the use of catheterized samples is recommended whenever possible, and careful interpretation is required when using samples obtained by void.
It is possible that baseline group differences contributed to our findings. However, since UUI incidence increases with age and is therefore linked to menopause status, our sample size is not sufficient to further describe the separate effects of estrogen status, age, and UUI symptoms in relation to microbiota diversity. We acknowledge this possibility; yet, we emphasize the importance of findings between treatment response groups (Fig. 2) . Women with one to four bacterial isolates on EQUC were most likely to respond to the initial 5-mg dose of solifenacin, whereas women with more diversity (≥5 bacterial isolates) were less likely to respond or needed an increased dose. These simple cutoffs, detectable prior to treatment, will require validation in larger patient populations. Therefore, in future studies, the use of both EQUC and sequencing for all collected urine specimens is recommended. The results are highly complementary, with sequencing measuring a broad picture of the population and the EQUC protocol measuring the cultivatable organisms within that population.
Clinicians can benefit from expanded knowledge about bacterial communities present in patients with UUI. Although specific changes in clinical management cannot yet be recommended, this promising area of research is generating many new hypotheses. In addition, our findings should inform the design of larger clinical studies that have potential to personalize UUI treatment, provide insight into UUI etiology, and offer promise for novel UUI prevention strategies. We believe that related urinary tract disorders may also benefit from this new knowledge.
Conclusions
The response to orally administered medication to treat UUI (solifenacin) may relate to individual urinary microbiota characteristics that are detectable prior to treatment. Our findings, especially the importance of organism diversity, offer promising possibilities for new ideas for prevention and treatment of UUI in women.
